INTRODUCTION
Immunization of humans with purified capsular polysaccharides of the pneumococcus has long been known to protect against nasopharyngeal carriage of and systemic infection by homologous strains (1) . Similar results have recently been reported with the capsular polysaccharide isolated from a group C meningococcus (2) . Evidence cited or reported in an accompanying communication (3) indicates that human antibodies to polyribophosphate (PRP),' the capsular antigen of H. influenzae, type b, may protect against infections by this bacterium. Humans can acquire these antibodies by asympto-matic (4) or clinical (5) infection with the organism, and anti-PRP antibodies can be induced in animals by immunization with bacterial cultures, if encapsulation is intact (6) . Attempts to elicit antibodies in either humans or animals with the isolated capsular antigen, however, have not been reported. The present paper describes the results of immunization of human adult volunteers with purified PRP.
METHODS
Polyribophosphate. PRP, sodium salt, was isolated from H. influenzae b, strain Eagan (3), by a modification2 of the method of Zamenhof and Leidy (7) . Chemical assays on the preparation (Table I) were done as follows: pentose, by the orcinol method using D-ribose as the standard (8) ; phosphate, by the Fiske-Subbarow method (9) ; sodium, by flame photometry with a lithium internal standard (model 143; Instrumentation Laboratory Inc., Watertown, Mass.); protein, by the Lowry, Rosebrough, Farr, and Randall method (10) with bovine albumin as standard; and nucleic acid (roughly), by optical density at 260 nm, assuming El cm = 250. An equimolar ratio of pentose, organic phosphate, and sodium was found, corresponding to the description of PRP by Zamenhof and colleagues (11, 12) . These three moieties account for two-thirds of the weight obtained by drying a sample of PRP solution to constant weight at 1000 C; since residual water may be trapped in the resulting film, their proportion of the actual dry weight may be closer to unity. Because of the difficulty in controlling moisture content, the PRP concentration of solutions was quantitated by pentose assay. Assuming a formula weight of 225 for one sodium phosphoribosyl unit (11), 1 lAg of pentose was taken to equal 1.5 ,ug of the polymer.
The pentose and phosphorus of the preparation was completely precipitable by rabbit antiserum to strain Eagan. In Ouchterlony gel diffusion the preparation formed a sinigle precipitin line, which was identical with the major of two lines formed by a soniic extract of strain Eagani. Electrophoresis in gel followed by precipitation with antiserum produced a single arc (Fig. 1) . ' Anderson, P., and D. H. Smith. Manuscript in preparation. Fig. 2 . The specifications of the Division of Biologics Standards were used in testing the injectable preparation for sterility and animal toxicity. In the latter, mice receiving 100 ,ug and guinea pigs receiving 500 ,ug intraperitoneally were found to gain weight normally. When pyrogen-tested intravenously in rabbits, the PRP solution was nonpyrogenic at 0.5 pg/kg (near the maximum human dose); injections of 50 ug/kg and 750 ,ug/kg produced slight fever, but no other observable effect.
Population iminunized. Recipients of PRP were volunteers from the groups of adults whose preimmunization titers in type b bactericidal and passive hemagglutiniation assays had been determined (3) . Initially, only those with relatively low titers were given PRP, and intradermal injection was employed for clear observation of local responses. After some experience, volunteers with relatively high titers and the subcutaneous route were included in the study.
Antibody assays. The collectioni and storage of sera, the anitibody assays, and the test strain H. influenzae b-Eagan have been described (3) . Multiple serum samples from the same individual were tested simultaneously. Experimental inifection of rats with H. influenzac b. To prepare bacteria for experimental infection chocolate agar slants were inoculated, and after 5 hr of incubation the cells were suspended in 0.15 M NaCl. The suspension was chilled in ice water, and its optical density was determined. The bacteria were immediately diluted in 0.15 M NaCl to 10-fold the desired concentration and then diluted 1: 10 in a diluent consisting of 0.15 M NaCl plus 5% hog gastric mucin (Wilson Laboratories, Chicago, Ill.) with the pH adjusted to 7 with NaOH after autoclaving. This suspension was held at 0'C and used within 1 hr. SpragueDawley rats (COBS-CD; Charles River Breeding Labs, Inc., Wilmington, Mass.) were obtained as weanlings (about 21 days old) and challenged 1 day after delivery to the new quarters. The rats received 0.5 ml of the bacterial suspension intraperitoneally, and survival was scored twice daily.
RESULTS
Kinetics of antibody response. Three initial recipients were injected intradermally with 10, 50, or 55 Ag PRP, and frequent serum samples were taken for passive hemagglutination (PHA) assay and serum bactericidal (BC) and opsonization assays against H. influenzae strain b-Eagan (Fig. 3) . In all three recipients PHA and BC activity increased sharply at about 1 wk, ceased rising by 2 wk, and remained stable for at least 16 wk. FIGURE 1 Immunoelectrophoresis of the polyribophosphate preparation. The anode was to the right. The antigen preparation, 250 Ag PRP/ml, was put in the center well. After electrophoresis 30 min at 30 ma and at room temperature, the troughs were filled with antisera to H. influenzae, type b: lower, to strain Eagan; upper, to strain 62B. After overnight incubation and thorough washing, the slide was stained with Ponceau S. To explore the effect of dose on the persistence of the response, the PHA and BC titers at 2-3 wk and at 24 wk were compared in the above three plus five additional recipients of doses varying from 1 to 55 i,g. In PHA activity all eight had responded sharply by 2-3 wk and maintained identical titers through 24 wk, with the possible exception of a one dilution drop in two recipients immunized with 10 and 55 Ag. In seven of the eight individuals the BC titers had increased sharply by 2-3 wk, and in all seven the 24 wk titer was identical with that at 2-3 wk. One recipient of 55 ug (preimmunization titer of 16) The numbers and design are not adequate for a definitive consideration of the relative amounts of antibody generated; however, a relation of dose to antibody increase was apparent: among only those individuals with significant increases (last column) intradermal doses of 1 ,ug gave greater rises than 0.1 /g (for BC, P < 0.001; for PHA, P = 0.072) but less than 50 lAg (for BC, P < 0.001; for PHA, P = 0.006). A similar relationship was found with subcutaneous injections. Intradermal and subcutaneous injections were equally effective in producing significant rises. The former route, however, seemed to generate larger increases at the higher doses. Significant mean differences between the two routes were found in PHA at 1 uLg (P = 0.016) and at 10 ug (P = 0.046). Intradermal doses of 50 iAg produced greater rises than 100 ,tg subcutaneously in both BC (P = 0.002) and PHA (P = 0.036).
Not evident in the Opsonization activity is given in the unit A OD, 515 nm (3). Anderson, Peter, Johnston, Wetterlow, and Smith were produced by the subcutaneous injections; four of seven recipients of the 100 ,ug doses reported a slight tenderness. Two individuals, both recipients of 10 ,ug intradermally, reported systemic symptoms: one had headache, malaise, and fatigue the following day, and the other had a mild frontal headache lasting about a week. Causative factors other than the injections, however, could not be excluded. One of the five recipients of a 1 'g booster dose had an immediate wheal and flare response, which attained a maximal diameter of 25 mm at J hr and disappeared within 3 hr. The individual manifesting this reaction had 60 iAg of precipitable anti-PRP antibody/ml of serum (PHA titer of 320) at the time of reimmunization.
Immunization with Polyribophosphate
Passive immunization with anti-PRP serum. The activity of the human antibody elicited by PRP was further explored through passive protection in experimental infection of weanling rats (Table III) . Postimmunization serum, 0.4 ml, given intravenously 1 hr before infection protected the animals against roughly 10 times the LD5o dose of H. influenzae b given intraperitoneally; 0.4 ml of preimmunization serum of the same individual had no protective effect.
Immunization of experimental animals. Preliminary attempts to demonstrate an antibody response to PRP in laboratory animals have been negative. Mice, rats, and rabbits given a wide range of doses by several routes and schedules never developed serum PHA activity. The rabbits failing to respond to PRP had not been rendered tolerant, for when subsequently immunized with formalin-killed H. influenzae b, they responded with the normal high titers of PHA activity.
DISCUSSION
In normal adults as little as 0.1 Ag of PRP elicited significant increases in antibody titer. Higher doses, however, generated somewhat greater increases. Thus, per unit weight, PRP appears to be comparably potent with pneumococcal (14) or meningococcal (15) polysaccharides as a human immunogen. Antibody activities to PRP remained at constant, maximal levels for at least 6 months. Such kinetics are characteristic of other bacterial polysaccharides and have been suggested to result from persistence of these antigens in the immune system (14) .
In general, serum bactericidal and opsonizing activities against H. influenzae b rose in parallel with activity in the PRP-specific PHA assay. There were, however, four recipients in which a relatively high bactericidal titer did not rise along with an increase in PHA. A possible explanation is offered by the finding that bactericidal activity of anti-PRP antibodies can be masked by bactericidal antibodies directed against somatic antigens (3) .
Of the 53 recipients with antibody rises, 30 had had prior experience with the antigen as evidenced by detectable PHA activity, while 23 had preimmunization titers of <2. The relative increase in the two groups, however, was not significantly different. It seems likely that the latter group also had had previous experience with the antigen but that their circulating antibody had dropped below the detectable limit. The possibility is not excluded, however, that this was their first immunizing contact with the antigen and thus that initial and subsequent responses to PRP can be similar. Booster injections of 1 Ag given at 6 months, when antibody titers were still maximal, did not increase the titers. This result may have a trivial explanation-a higher dose or different route of administering the antigen might have worked. The reason for the failure, however, might be fundamental. Second injections of pneumococcal polysaccharides do not further increase antibody titers in humans (14) . Mice immunized with SIII (16) and rab- (16) .
Immediate dermal wheal and flare reactions had been observed after the intradermal inoculation of PRP in some patients given therapeutic doses of rabbit anti-H. influenzae b serum intravenously (18) . For this reason the initial immunization studies were performed primarily with low doses of antigen in individuals with low PHA titers. An immediate wheal and flare was observed only at the reimmunization of one individual, who at the time had a high serum concentration of anti-PRP antibody. A tuberculin-like reaction, however, was manifested by many individuals immunized intradermally. Unlike the reactions provoked by vaccines containing endotoxin, it was delayed, was not accompanied by local pain or systemic symptoms, and was not observed in individuals immunized subcutaneously. Conceivably, this delayed response to PRP is cell mediated. It will therefore be of interest in further studies to observe the reaction to PRP of individuals with deficient cellular immunity and infants who have not had contact with H. influenzae b, and to investigate the mitogenic activity of PRP in lymphoid cells in vitro.
The experimental infection of rats, in which anti-PRP human serum was protective, is a promising model for study of the pathogenesis of H. influenzae. Animals succumbing are found to have a massive bacteremia, and the virulence of various strains is well correlated with their status of encapsulation.
H. influenzae type b is the most common cause of bacterial meningitis in infants and young children (19) 
